Akebia Therapeutics (AKBA) Reports In-Line Q2 EPS
Get Alerts AKBA Hot Sheet
Join SI Premium – FREE
Akebia Therapeutics (NASDAQ: AKBA) reported Q2 EPS of ($0.04), in-line with the analyst estimate of ($0.04). Revenue for the quarter came in at $43.65 million versus the consensus estimate of $49.47 million.
For earnings history and earnings-related data on Akebia Therapeutics (AKBA) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Winnebago Industries (WGO) PT Lowered to $40 at Benchmark on Pressured NT Demand
- Teleflex starts global pivotal trial for resorbable magnesium scaffold
- Mizuho Reiterates Outperform Rating on EyePoint Inc. (EYPT)
Create E-mail Alert Related Categories
EarningsRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!



Tweet
Share